Brean Capital set a $48.00 target price on Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a report published on Thursday morning. The brokerage currently has a a buy rating on the stock.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Several other equities research analysts also recently commented on the company. Stifel Nicolaus lifted their price objective on Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a buy rating in a report on Thursday, September 15th. Needham & Company LLC reiterated a buy rating and issued a $52.00 price objective (up from $45.00) on shares of Aerie Pharmaceuticals in a report on Thursday, September 15th. Cantor Fitzgerald lifted their price objective on Aerie Pharmaceuticals from $44.00 to $50.00 and gave the stock a buy rating in a report on Thursday, September 15th. Royal Bank Of Canada lifted their price objective on Aerie Pharmaceuticals from $51.00 to $55.00 and gave the stock an outperform rating in a report on Thursday, September 15th. Finally, Raymond James Financial Inc. assumed coverage on Aerie Pharmaceuticals in a report on Tuesday, September 13th. They issued an outperform rating and a $48.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $47.56.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 34.12 on Thursday. The stock has a 50 day moving average of $20.33 and a 200-day moving average of $16.95. The stock’s market capitalization is $951.68 million. Aerie Pharmaceuticals has a one year low of $10.82 and a one year high of $35.32.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. Equities analysts forecast that Aerie Pharmaceuticals will post ($2.77) earnings per share for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. acquired 250,000 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $4,375,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 8.77% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. increased its position in shares of Aerie Pharmaceuticals by 25.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,544 shares of the company’s stock worth $661,000 after buying an additional 7,700 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of Aerie Pharmaceuticals by 16.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,893 shares of the company’s stock worth $315,000 after buying an additional 2,544 shares during the period. Iguana Healthcare Management LLC increased its position in shares of Aerie Pharmaceuticals by 100.0% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the company’s stock worth $2,640,000 after buying an additional 75,000 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock worth $36,960,000 after buying an additional 75,000 shares during the period. Finally, Barclays PLC increased its position in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the period. Institutional investors own 99.66% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.